IOME Bio develops microbiome-based mechanisms to enhance the efficacy of immuno-oncology therapies by utilizing first-in-class monoclonal antibodies that amplify immune responses. The company specifically targets resistance to PD-1 blockade, aiming to improve treatment outcomes for cancer patients.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients develop resistance to PD-1 blockade, a common form of immuno-oncology therapy, limiting the effectiveness of these treatments. This resistance leads to poorer outcomes and a continued need for more effective therapeutic strategies.
Solution
IOME Bio is developing a new class of monoclonal antibodies designed to enhance the efficacy of immuno-oncology therapies, specifically addressing resistance to PD-1 blockade. Their approach leverages unique mechanistic insights into the microbiome's role in modulating immune responses to cancer. By targeting novel pathways, IOME Bio aims to amplify the body's natural defenses against tumors and improve treatment outcomes for patients who do not respond to existing therapies. The company's technology is based on foundational research and intellectual property licensed from Harvard University.
Target Audience
The primary target audience includes cancer patients who have developed resistance to PD-1 blockade, as well as oncologists and researchers seeking new therapeutic options for these patients.
Features
- First-in-class monoclonal antibodies targeting novel immuno-oncology targets
- Focus on overcoming resistance to PD-1 and other checkpoint inhibitors
- Exclusive option to license new IP arising from ongoing sponsored research at Harvard
- Proprietary mechanistic insights into microbiome-immune interactions